Ultimovacs ASA

CHIX:ULTIo (Norway)   Ordinary Shares
kr 100.20 (0%) Apr 26
At Loss
P/B:
1.02
Market Cap:
kr 244.28M ($ 22.13M)
Enterprise V:
kr -18.56M ($ -1.68M)
Volume:
-
Avg Vol (2M):
-
Also Trade In:
Volume:
-
At Loss

Business Description

Description
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.
Name Current Vs Industry Vs History
Cash-To-Debt 71.79
Equity-to-Asset 0.8
Debt-to-Equity 0.01
Debt-to-EBITDA -0.02
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.85
Quick Ratio 4.85
Cash Ratio 4.75

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2.4
Shareholder Yield % -0.59